Welcome to MS Views and News blog

MS Views and News, empowers those affected by Multiple Sclerosis (MS) with educational information, resources and services. Please scroll downward to find articles or videos of interest, then click to open the document or video.

Categories

Latest Blog Posts

July 10, 2022

Nimhans to study impact of yoga on multiple sclerosis patients

  • Alternative therapies and devices for Multiple Sclerosis (MS)
    /
 The project is funded by the Department of Science and Technology DHNS, Bengaluru,  JUL 08 2022,  The National Institute of…
Alternative therapies and devices for Multiple Sclerosis (MS)

July 10, 2022

Video: ‘Getting Back to Normal’ – Adapting & Changes for the MS Community since the beginning of Covid

  • Alternative therapies and devices for Multiple Sclerosis (MS)
    /
  • For the Benefit of the Patient
    /
  After watching this video, visit our Youtube Learning channel: www.youtube.com/msviewsandnews Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews…
Alternative therapies and devices for Multiple Sclerosis (MS)

July 10, 2022

video: Listen with Suzanne O’Connell, MS Patient Advocate/ founder of Multiple Sclerosis Alliance of Virginia discusses this MS organizations’ role in rural VA

  • Additional MS resource sites
    /
  • An MS Patients Story
    /
  Click to Subscribe for the MS Beacon eNewsletter and MS educational events Visit our MS Learning Channel on YouTube:…
Additional MS resource sites

July 10, 2022

A compass to MS Care Rural America – from Lynchburg, VA

  • MS Drug Therapies
    /
  • MS Educational Programs
    /
  • Multiple Sclerosis
    /
  • Multiple Sclerosis Videos
    /
  • Wellness for MS
    /
  Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews…
MS Drug Therapies

July 9, 2022

Diroximel Fumarate for Relapsing MS: How Does It Affect Clinical Outcomes?

  • MS Drug Therapies
    /
  • MS Research Study and Reports
    /
 June 8, 2022 – Mary Stroka The most frequent AEs were flushing (32.3%), nasopharyngitis (24.6%), and MS relapse during treatment with…
MS Drug Therapies

July 8, 2022

Ocrelizumab Reduces Thalamic Volume Loss

  • Additional MS resource sites
    /
  • MS Research Study and Reports
    /
Ocrelizumab Reduces Thalamic Volume Loss, – Cenobamate Shines in C017 Study, Trial of LRRK2 Inhibitor BIIB122 Commences Using the phase 3…
Additional MS resource sites

July 6, 2022

Biosimilar and Interchangeable Biologics: More Treatment Choices

  • MS Specialty Pharmacy
    /
  • Multiple Sclerosis
    /
The U.S. Food and Drug Administration has approved biosimilar medications to treat conditions such as cancer, diabetes, Crohn’s disease, colitis,…
MS Specialty Pharmacy

July 6, 2022

UK Study: Fatigue Often Influences Quality of Life in MS

  • Multiple Sclerosis
    /
  • Multiple Sclerosis (MS) Symptoms
    /
 by Lindsey Shapiro, PhD | June 30, 2022 Fatigue is a common symptom among people living with multiple sclerosis (MS),…
Multiple Sclerosis

July 4, 2022

Media Update: Patient enrollment of phase III tolebrutinib trials paused in the U.S.

  • MS Research Study and Reports
    /
 Paris, June 30, 2022. The U.S. Food and Drug Administration (FDA) has placed Phase 3 studies of tolebrutinib in multiple sclerosis (MS)…
MS Research Study and Reports

July 4, 2022

Peace out: Roche’s Genentech adopts V hand signal in next-gen Ocrevus campaign for multiple sclerosis

  • Ocrevus
    /
Beth Snyder Bulik -Senior Editor The two-finger V sign debuted in Roche’s Genentech first TV commercial for multiple sclerosis treatment…
Ocrevus

Categories

Latest Blog Posts